Announced Thu, 16 Jul · 13:52 IST
Routine compliance certificate filed with BSE for Q1 FY27
Compliance View source PDF
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Price reaction · full curve 14 horizons · vs prior close
-5.6%1-day move
₹71.00
prior close
—
base price
In-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
————-5.6-6.5-1.8-1.4-4.0+3.4————
Up moveDown movePending
AI summary
Novelix Pharmaceuticals submitted a certificate from its Registrar and Share Transfer Agent, Venture Capital and Corporate Investments, under SEBI Regulation 74(5) for the quarter ended 30 June 2026. The certificate confirms that no securities were received for dematerialisation or rematerialisation during the quarter. This is a standard quarterly compliance filing with no change in share capital activity.
Likely market impact
Routine regulatory filing with no impact on shareholders or stock price. Confirms no share conversion activity in the quarter.